Eton Pharmaceuticals (ETON) Cash from Investing Activities (2020 - 2025)
Eton Pharmaceuticals (ETON) posted Cash from Investing Activities of -$49000.0 for Q4 2025, up 82.75% sequentially from -$284000.0 in Q3 2025, and up 99.87% YoY from -$24515.8 in Q4 2024.
Eton Pharmaceuticals (ETON) Cash from Investing Activities (2020 - 2025) Analysis & Trends
Eton Pharmaceuticals has reported Cash from Investing Activities for 6 years, with the latest figure at -$49000.0 in Q4 2025.
- Quarterly Cash from Investing Activities rose 99.87% year-over-year to -$49000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$333000.0 (up 99.17% YoY) and the FY2025 annual result came in at -$333000.0, up 99.17% from the prior year.
- Cash from Investing Activities climbed to -$49000.0 in Q4 2025 per ETON's latest filing, from -$284000.0 in the prior quarter.
- Over five years, Cash from Investing Activities peaked at -$2000.0 in Q3 2021 and troughed at -$38.1 million in Q4 2024.
- A 5-year average of -$4.3 million and a median of -$761000.0 in 2022 frame the typical range for Cash from Investing Activities.
- The sharpest annual moves came in 2022 and 2025: Cash from Investing Activities plunged 99900.0% in 2022, then soared 99.87% in 2025.
- Over 5 years, Cash from Investing Activities stood at -$3.3 million in 2021, then jumped by 99.63% to -$12000.0 in 2022, then plunged by 6358.33% to -$775000.0 in 2023, then slumped by 4820.26% to -$38.1 million in 2024, then surged by 99.87% to -$49000.0 in 2025.
- According to Business Quant data, Cash from Investing Activities over the past three periods registered -$49000.0, -$284000.0, and -$38.1 million for Q4 2025, Q3 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -491.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | -300.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -550.24 Mn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 87.50 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -51.60 Mn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | -135.40 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | -110.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Eton Pharmaceuticals | 1.65 Bn | 1.62 Bn | 25.41 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -49,000.00 |
| Dec 31, 2025 | -49,000.00 |
| Sep 30, 2025 | -284,000.00 |
| Sep 30, 2025 | -284,000.00 |
| Dec 31, 2024 | -38.13 Mn |
| Dec 31, 2024 | -38.13 Mn |
| Mar 31, 2024 | -1.88 Mn |
| Mar 31, 2024 | -1.88 Mn |
| Dec 31, 2023 | -775,000.00 |
| Dec 31, 2023 | -775,000.00 |
| Dec 31, 2022 | -12,000.00 |
| Dec 31, 2022 | -12,000.00 |
| Sep 30, 2022 | -2.00 Mn |
| Sep 30, 2022 | -2.00 Mn |
| Jun 30, 2022 | -761,000.00 |
| Jun 30, 2022 | -761,000.00 |
| Mar 31, 2022 | -15,000.00 |
| Mar 31, 2022 | -15,000.00 |
| Dec 31, 2021 | -3.25 Mn |
| Dec 31, 2021 | -3.25 Mn |